Contemporary radiation countermeasures

Vivek N. Patel, Seema Gupta, Mohammed M. Shareef, Mansoor M. Ahmed

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Radiation countermeasures have been investigated for decades, but the search for ideal protective agents for use prior to or after irradiation still continues. This review focuses on agents that have demonstrated as potential as in vivo countermeasure agents and may subsequently be effectively used in human beings. Such agents are categorised as radioprotectors, radiation mitigators, or therapeutic agents dependening upon their time of administration. These protective or mitigating agents are designed to reduce inadvertent damage to normal tissue caused by radiation. These interventions function via various mechanisms of action ranging from modulating signalling pathways to inhibiting cell death, cytokines, and growth factor. Many agents demonstrated promising results in murine models and are being tested in human beings. Amifostine, and curcumin have shown radioprotection, while genistein, palifermin, and halofuginone have been shown to alleviate the side effects in patients undergoing radiotherapy. Though these compounds show some promise as radiation countermeasure agents, there are several associated limitations and the search for perfect agents still continues.

Original languageEnglish (US)
Pages (from-to)138-145
Number of pages8
JournalDefence Science Journal
Volume61
Issue number2
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

countermeasures
Radiation
radiation
Amifostine
Fibroblast Growth Factor 7
Protective Agents
Curcumin
Genistein
Radiotherapy
Cell death
death
Intercellular Signaling Peptides and Proteins
radiation therapy
Irradiation
Tissue
Cytokines
damage
irradiation

Keywords

  • Radiation counter measures
  • Radiation mitigators
  • Radioprotectors
  • Radiotherapy
  • Therapeutic agents

ASJC Scopus subject areas

  • Chemical Engineering(all)
  • Electrical and Electronic Engineering
  • Mechanical Engineering
  • Computer Science Applications
  • Physics and Astronomy(all)
  • Biomedical Engineering

Cite this

Patel, V. N., Gupta, S., Shareef, M. M., & Ahmed, M. M. (2011). Contemporary radiation countermeasures. Defence Science Journal, 61(2), 138-145.

Contemporary radiation countermeasures. / Patel, Vivek N.; Gupta, Seema; Shareef, Mohammed M.; Ahmed, Mansoor M.

In: Defence Science Journal, Vol. 61, No. 2, 03.2011, p. 138-145.

Research output: Contribution to journalArticle

Patel, VN, Gupta, S, Shareef, MM & Ahmed, MM 2011, 'Contemporary radiation countermeasures', Defence Science Journal, vol. 61, no. 2, pp. 138-145.
Patel VN, Gupta S, Shareef MM, Ahmed MM. Contemporary radiation countermeasures. Defence Science Journal. 2011 Mar;61(2):138-145.
Patel, Vivek N. ; Gupta, Seema ; Shareef, Mohammed M. ; Ahmed, Mansoor M. / Contemporary radiation countermeasures. In: Defence Science Journal. 2011 ; Vol. 61, No. 2. pp. 138-145.
@article{51ffcc7cf5e04ccf9468fd4a523f7861,
title = "Contemporary radiation countermeasures",
abstract = "Radiation countermeasures have been investigated for decades, but the search for ideal protective agents for use prior to or after irradiation still continues. This review focuses on agents that have demonstrated as potential as in vivo countermeasure agents and may subsequently be effectively used in human beings. Such agents are categorised as radioprotectors, radiation mitigators, or therapeutic agents dependening upon their time of administration. These protective or mitigating agents are designed to reduce inadvertent damage to normal tissue caused by radiation. These interventions function via various mechanisms of action ranging from modulating signalling pathways to inhibiting cell death, cytokines, and growth factor. Many agents demonstrated promising results in murine models and are being tested in human beings. Amifostine, and curcumin have shown radioprotection, while genistein, palifermin, and halofuginone have been shown to alleviate the side effects in patients undergoing radiotherapy. Though these compounds show some promise as radiation countermeasure agents, there are several associated limitations and the search for perfect agents still continues.",
keywords = "Radiation counter measures, Radiation mitigators, Radioprotectors, Radiotherapy, Therapeutic agents",
author = "Patel, {Vivek N.} and Seema Gupta and Shareef, {Mohammed M.} and Ahmed, {Mansoor M.}",
year = "2011",
month = "3",
language = "English (US)",
volume = "61",
pages = "138--145",
journal = "Defence Science Journal",
issn = "0011-748X",
publisher = "Defense Scientific Information and Documentation Centre",
number = "2",

}

TY - JOUR

T1 - Contemporary radiation countermeasures

AU - Patel, Vivek N.

AU - Gupta, Seema

AU - Shareef, Mohammed M.

AU - Ahmed, Mansoor M.

PY - 2011/3

Y1 - 2011/3

N2 - Radiation countermeasures have been investigated for decades, but the search for ideal protective agents for use prior to or after irradiation still continues. This review focuses on agents that have demonstrated as potential as in vivo countermeasure agents and may subsequently be effectively used in human beings. Such agents are categorised as radioprotectors, radiation mitigators, or therapeutic agents dependening upon their time of administration. These protective or mitigating agents are designed to reduce inadvertent damage to normal tissue caused by radiation. These interventions function via various mechanisms of action ranging from modulating signalling pathways to inhibiting cell death, cytokines, and growth factor. Many agents demonstrated promising results in murine models and are being tested in human beings. Amifostine, and curcumin have shown radioprotection, while genistein, palifermin, and halofuginone have been shown to alleviate the side effects in patients undergoing radiotherapy. Though these compounds show some promise as radiation countermeasure agents, there are several associated limitations and the search for perfect agents still continues.

AB - Radiation countermeasures have been investigated for decades, but the search for ideal protective agents for use prior to or after irradiation still continues. This review focuses on agents that have demonstrated as potential as in vivo countermeasure agents and may subsequently be effectively used in human beings. Such agents are categorised as radioprotectors, radiation mitigators, or therapeutic agents dependening upon their time of administration. These protective or mitigating agents are designed to reduce inadvertent damage to normal tissue caused by radiation. These interventions function via various mechanisms of action ranging from modulating signalling pathways to inhibiting cell death, cytokines, and growth factor. Many agents demonstrated promising results in murine models and are being tested in human beings. Amifostine, and curcumin have shown radioprotection, while genistein, palifermin, and halofuginone have been shown to alleviate the side effects in patients undergoing radiotherapy. Though these compounds show some promise as radiation countermeasure agents, there are several associated limitations and the search for perfect agents still continues.

KW - Radiation counter measures

KW - Radiation mitigators

KW - Radioprotectors

KW - Radiotherapy

KW - Therapeutic agents

UR - http://www.scopus.com/inward/record.url?scp=79952260580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952260580&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 138

EP - 145

JO - Defence Science Journal

JF - Defence Science Journal

SN - 0011-748X

IS - 2

ER -